Autism Spectrum Disorder Therapeutics Market, By Drug Types (Insomnia Drugs, Selective Serotonin Reuptake Inhibitors, Anticonvulsants, and Antipsychotics), By Indication, By Distribution Channel and Geography (North America, Europe, Asia Pacific, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025

  • Product Code:
    RP-ID-10294048
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    130
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-48

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

ccs

Market Overview:

REPORT HIGHLIGHT

The autism spectrum disorder therapeutics market was valued at USD 2.68 billion by 2017, growing with 3.4% CAGR during the forecast period, 2018-2025

Market Dynamics

Autism spectrum disorder includes a class of neuro-developmental disabilities. Some of the prominent disorders that come under the umbrella term of autism spectrum disorder are pervasive personality disorder-not otherwise specified, Asperger’s syndrome, and autism. Autism spectrum disorder therapeutics concerns with various treatment options such as behavioral therapy, which is usually considered as the first-line treatment. Patients are also given pharmacological therapies to help them function properly in their daily lives.

Autism spectrum disorder therapeutics companies are observed to continuously introduce innovative solutions in the global market after receiving approval from regulatory authorities. In April 2019, Finch Therapeutics Group, a US developer of microbial therapies, received FDA’s Fast Track designation for its Full-Spectrum Microbiota therapy. According to the company, the therapy is aimed at treating autism spectrum disorder in children.

The growing number of autism patients is anticipated to increase the demand for autism spectrum disorder therapeutics. Companies are coming up with various novel products and have a number of drugs in the pipeline for autism treatment. Moreover, there has been a rise in the manufacture of generic pharmaceutical products used to treat autism. All of these factors are expected to push the growth of the global autism spectrum disorder therapeutics market. In addition, companies are investing heavily in research and development to introduce new products in the global market. However, tight regulations and policies associated with product approval are foretold to pose a challenge to players operating in the global autism spectrum disorder therapeutics market.

Drug Type Takeaway

The segment of insomnia drugs is projected to exhibit robust growth in the global autism spectrum disorder therapeutics market. In April 2019, the FDA announced that it will require certain prescription insomnia medicine manufacturers to issue a new boxed warning. The announcement comes after the reporting of several cases of deaths and serious injuries caused due to complex sleep behaviors after taking the medicines. Among indication segments, insomnia could secure a significant share of the global market. Analysts expect hospital pharmacies to collect a leading share of the global market, among distribution channels.

Regional Takeaway

Regionally, North America is forecast to show healthier growth in the global autism spectrum disorder therapeutics market because of the rising awareness about autism, increasing incidence of the disorder, and new product development. Europe could be another high-growth regional market gaining from the increase in research and development activities and rising number of autism awareness programs.

Key Players

The global autism spectrum disorder therapeutics market witnesses the presence of top players such as Actavis, Inc., Curemark LLC, Janssen Pharmaceuticals, Inc., Otsuka Holdings Co., Ltd., Pediatric BioScience, Inc., Teva Pharmaceutical Industries Ltd., Mylan Pharmaceuticals, Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Merck & Co., and Par Sterile Products, LLC.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE

Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY DRUG CLASS

Insomnia Drugs
Selective Serotonin Reuptake Inhibitors
Anticonvulsants
Antipsychotics
Others
MARKET, BY INDICATION

Insomnia
Epilepsy
Depression
Hyperactivity and Inattention
Others
MARKET, BY DISTRIBUTION CHANNEL

Hospital Pharmacies
Retail Pharmacies
Others
MARKET, BY REGION

North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America


Geography Analysis:


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC(Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa  (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

.

FREQUENTLY ASKED QUESTIONS

TABLE OF CONTENT

1. AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Drug Class
2.1.2. Market Snippet by Indication
2.1.3. Market Snippet by Distribution Channel
2.1.4. Market Snippet by Region
2.2. Competitive Insights
3. AUTISM SPECTRUM DISORDER THERAPEUTICS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. AUTISM SPECTRUM DISORDER THERAPEUTICS INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET LANDSCAPE
5.1. Market Share Analysis
5.2. Key Innovators
5.3. Breakdown Data, by Key manufacturer
5.3.1. Established Player Analysis
5.3.2. Emerging Player Analysis
6. AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET – BY DRUG CLASS
6.1. Overview
6.1.1. Segment Share Analysis, By Drug Class, 2017 & 2025 (%)
6.2. Insomnia Drugs
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.3. Selective Serotonin Reuptake Inhibitors
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.4. Anticonvulsants
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.5. Antipsychotics
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
6.6. Others
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7. AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET – BY INDICATION
7.1. Overview
7.1.1. Segment Share Analysis, By Indication, 2017 & 2025 (%)
7.2. Insomnia
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.3. Epilepsy
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.4. Depression
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.5. Hyperactivity and Inattention
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
7.6. Others
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8. AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET – BY DISTRIBUTION CHANNEL
8.1. Overview
8.1.1. Segment Share Analysis, By Distribution Channel, 2017 & 2025 (%)
8.2. Hospital Pharmacies
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.3. Retail Pharmacies
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
8.4. Others
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9. AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET– BY GEOGRAPHY
9.1. Introduction
9.1.1. Segment Share Analysis, By Region, 2017 & 2025 (%)
9.2. North America
9.2.1. Overview
9.2.2. Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2014 – 2025 (US$ Million)
9.2.4. North America Market Size and Forecast, By Drug Class, 2014 – 2025 (US$ Million)
9.2.5. North America Market Size and Forecast, By Indication, 2014 – 2025 (US$ Million)
9.2.6. North America Market Size and Forecast, By Distribution Channel, 2014 – 2025 (US$ Million)
9.2.7. U.S.
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.2.8. Canada
9.2.8.1. Overview
9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2014 – 2025 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Drug Class, 2014 – 2025 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Indication, 2014 – 2025 (US$ Million)
9.3.6. Europe Market Size and Forecast, By Distribution Channel, 2014 – 2025 (US$ Million)
9.3.7. France
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.3.8. Germany
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.3.9. Rest of Europe
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Key Manufacturers in Asia Pacific
9.4.3. Asia Pacific Market Size and Forecast, By Country, 2014 – 2025 (US$ Million)
9.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2014 – 2025 (US$ Million)
9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2014 – 2025 (US$ Million)
9.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2014 – 2025 (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.4.8. India
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.4.9. Rest of APAC
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.5. Rest of the World
9.5.1. Overview
9.5.2. Key Manufacturers in Rest of the World
9.5.3. Rest of the World Market Size and Forecast, By Country, 2014 – 2025 (US$ Million)
9.5.4. Rest of the World Market Size and Forecast, By Drug Class, 2014 – 2025 (US$ Million)
9.5.5. Rest of the World Market Size and Forecast, By Indication, 2014 – 2025 (US$ Million)
9.5.6. Rest of the World Market Size and Forecast, By Distribution Channel, 2014 – 2025 (US$ Million)
9.5.7. Latin America
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
9.5.8. Middle East and Africa
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Million)
10. KEY VENDOR ANALYSIS
10.1. Actavis, Inc.
10.1.1. Company Snapshot
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Strategic Initiatives
10.2. Curemark LLC
10.2.1. Company Snapshot
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Strategic Initiatives
10.3. Janssen Pharmaceuticals, Inc.
10.3.1. Company Snapshot
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Strategic Initiatives
10.4. Otsuka Holdings Co., Ltd.
10.4.1. Company Snapshot
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Strategic Initiatives
10.5. Pediatric BioScience, Inc.
10.5.1. Company Snapshot
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Strategic Initiatives
10.6. Teva Pharmaceutical Industries Ltd.
10.6.1. Company Snapshot
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Strategic Initiatives
10.7. Mylan Pharmaceuticals, Inc.
10.7.1. Company Snapshot
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Strategic Initiatives
10.8. Pfizer Inc.
10.8.1. Company Snapshot
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Strategic Initiatives
10.9. Novartis AG
10.9.1. Company Snapshot
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Strategic Initiatives
10.10. Bristol-Myers Squibb
10.10.1. Company Snapshot
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Strategic Initiatives
10.11. Merck & Co.
10.11.1. Company Snapshot
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Strategic Initiatives
10.12. Par Sterile Products, LLC
10.12.1. Company Snapshot
10.12.2. Financial Performance
10.12.3. Product Benchmarking
10.12.4. Strategic Initiatives
11. 360 DEGREE ANALYSTVIEW
12. APPENDIX
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports